GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » Beta

Adcock Ingram Holdings (JSE:AIP) Beta : 0.41 (As of Sep. 21, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-09-21), Adcock Ingram Holdings's Beta is 0.41.


Adcock Ingram Holdings Beta Historical Data

The historical data trend for Adcock Ingram Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adcock Ingram Holdings Beta Chart

Adcock Ingram Holdings Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.50 0.34 0.37 0.41

Adcock Ingram Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.45 0.37 0.31 0.41

Competitive Comparison of Adcock Ingram Holdings's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Adcock Ingram Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adcock Ingram Holdings's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adcock Ingram Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Adcock Ingram Holdings's Beta falls into.



Adcock Ingram Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Adcock Ingram Holdings  (JSE:AIP) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Adcock Ingram Holdings Beta Related Terms

Thank you for viewing the detailed overview of Adcock Ingram Holdings's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Adcock Ingram Holdings Business Description

Traded in Other Exchanges
N/A
Address
1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682
Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.